StudyRareStudyRare

Emery-Dreifuss muscular dystrophy

Log in to star

Last updated Nov 4, 2026

Log in to add personal notes on this page.

A teenager has elbow and ankle contractures and rigid spine. He has scapuloperoneal muscle weakness. His ECG shows heart block.

  • XLR: EMD (emerin, 8.5%) and FHL1 (1.2%); loss of function
  • AD, rarely AR: LMNA (lamin A/C, 26.5%); dominant negative or haploinsufficiency
  • Rare AD genes for nuclear envelope proteins: SYNE1, SYNE2, TMEM43 (dominant negative), SUN2; AR: SUN1
  • No variant is found in about 63%

Emerin, lamin A/C, and FHL1 help organize the nuclear envelope and interact with proteins of chromatin and the nuclear matrix. Two mechanisms, not mutually exclusive, are thought to cause the disease. First, the weakened envelope deforms and ruptures under the mechanical stress of skeletal and heart muscle, with DNA damage. Second, disordered chromatin changes gene expression, altering how muscle cells grow, differentiate, and signal.

  • EMD: null variants give the more severe picture; missense variants leave reduced or normal emerin and give milder disease or isolated heart disease. Emerin normally sits on the nuclear membrane of nearly every cell and is absent in 95% of people with the X-linked form, so immunostaining of buccal cells, skin, or muscle can support the diagnosis.
  • LMNA: one variant can cause Emery-Dreifuss, a limb-girdle pattern, or dilated cardiomyopathy with conduction disease within the same family. Missense variants tend toward early contractures, frameshift variants toward later limb-girdle weakness. Lamin staining does not confirm the AD form, because the normal allele still makes lamin A/C.
  • Early contractures (elbows, ankles, spine)
  • Slowly progressive weakness (humeroperoneal)
  • Cardiac: conduction defects, arrhythmias, cardiomyopathy - may need pacemaker/ICD
  • Clinical recognition of the triad: early joint contractures, humeroperoneal weakness, and cardiac conduction disease
  • Serum creatine kinase mildly to moderately elevated; EMG myopathic; muscle biopsy or cardiac MRI supportive
  • Confirm with molecular testing, typically a multigene panel including EMD (X-linked) and LMNA (autosomal dominant/recessive); emerin immunostaining on muscle or skin can support EMD-related disease
  • Cardiology surveillance is the priority: serial ECG/Holter and echocardiography; early pacemaker or ICD for conduction block or arrhythmia (sudden death risk even with mild weakness)
  • Physical therapy, stretching, and orthopedic management for contractures and spinal rigidity
  • Monitor respiratory function; anesthesia planning and at-risk relative screening for cardiac disease

"EDMD clinical triad": Elbow and ankle contractures, Dystrophy of muscles (humeroperoneal weakness), and cardiac conduction Defects. The clinical triad of contractures + weakness + heart involvement distinguishes EDMD from other muscular dystrophies.

"LMNA = LaMinopathy": LMNA mutations cause many different phenotypes including EDMD, dilated cardiomyopathy, CMT peripheral neuropathy, lipodystrophy, and Hutchinson-Gilford progeria. Lamins are intermediate fiLAMENt proteins.

Reference Links